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Abstract
Introduction: The study aimed to determine the risk factors for reduced bone
mineral density (BMD) among postmenopausal women.
Material and methods: Two hundred and fifty-three postmenopausal women
were included to the study. The study group consisted of 85 women with osteo-
porosis (mean age: 59.9 years) and 168 with osteopenia (mean age: 57.8 years).
Patients were assigned to groups according to their BMD measured in the lum-
bar spine, hip and femoral neck by dual X-ray absorptiometry. Bone formation
was assessed by measuring serum osteocalcin and bone resorption by meas-
uring serum C-terminal type I α-collagen chain telopeptide. 
Results: Multiple regression analysis for lumbar spine showed association of
age (p = 0.001), parental history of fracture (p = 0.05), use of hormone replace-
ment therapy (p = 0.034), bisphosphonates therapy (p < 0.001), calcium and
vitamin D supplements therapy (p = 0.001), oestradiol level (p = 0.007) and body
mass index (p < 0.001). Multiple regression analysis for femoral neck and hip
total showed association of age (p = 0.001), parental history of fracture (p = 0.049),
use of bisphosphonates (p < 0.03)) use of calcium and vitamin D supplements
(p = 0.039), oestradiol level (p = 0.047). All the variables together explain 40.4%
of variance in BMD for the lumbar spine and 25.6% of variance in BMD for
femoral neck and hip total. 
Conclusions: The present study demonstrated correlations between the vari-
ables and BMD, which are known and widely described in the literature. Osteo-
porosis and osteopenia in Polish subjects appear to be associated with several
known risk factors that are well described in the literature. 
Key words: bone mineral density, postmenopausal women, osteoporosis, osteope-
nia, multifactorial analysis.
Introduction
Loss of bone mineral density (BMD) is related to hormonal imbalance,
ageing, environmental factors, life style and genetic predisposition. The
above causes account for 50-80% of individual variability in bone mass.
Loss of bone mass in women occurs predominantly in the postmenopausal
period due to disturbances in the balance between bone resorption by
osteoclasts and bone formation by osteoblasts, which lead to reduction
in BMD [1]. Loss of BMD in women consists of two stages. It starts after
the menopause with an exponential decrease in BMD. This rapid process
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is oestrogen-dependent and lasts approximately 5-
10 years. Subsequently, it is followed by a constant
stage that is age-related. The sudden oestrogen-
dependent loss of bone mass after the menopause
accounts for 50% of the total loss in the thoracic
and lumbar spine and it is responsible for fractures
of the cancellous bone such as compression frac-
tures of vertebral bodies. The age-related loss of
bone mass causes thinning of bone trabeculae and
loss of bone tissue in the cortical layer. As a result
of this process, the cortex becomes porous, which
increases the susceptibility to fractures of the
femoral neck. The rate of BMD loss may be
assessed using biochemical markers of bone
remodelling. The markers may illustrate the enzy-
matic activity specific for osteogenic cells and cells
responsible for bone resorption or components of
cell matrix released to the blood during bone for-
mation or resorption [2].
The study aimed to determine which sociode-
mographic and clinical parameters represent risk
factors for reduced BMD among postmenopausal
women using multifactorial analysis.
Material and methods
Material
The study included 253 postmenopausal women
recruited from outpatients in the Menopause and
Osteoporosis Outpatient Clinic in Poznan between
1st August 2007 and 31st July 2008. In line with the
definition of the World Health Organization (WHO)
[3], subjects were classified as osteoporotic if their
T-score was 2.5 or more standard deviations (SD)
below the mean of young normal (T-score < –2.5),
and osteopenic if the lowest of these values was
between < –1.0 and > 2.5 SD (T-score < –1.0 and 
> –2.5 SD) in at least one of the measurement areas
(lumbar spine and hip total). In our study, patients
were assigned to two groups according to their
BMD measured in the lumbar spine and femoral
neck (T-score). The study group consisted of 85
women with osteoporosis (mean age: 59.9 years;
SD = 5.2) and 168 women with osteopenia (mean
age: 57.8 years; SD = 4.8).
An inclusion criterion was age between 50 and
70 years. Subjects with secondary osteoporosis,
metabolic bone disease, malignant bone metasta-
sis, hypogonadal states, osteogenesis imperfecta
and those treated with glucocorticoids were exclud-
ed. Endocrine, gastrointestinal, rheumatological and
haematological disorders were also among the
exclusion criteria. 
We obtained written consent of the patients for
their participation in the study. 
The study was approved by the Ethical Review
Committee at the Poznan University of Medical Sci-
ences. 
Measurements
Information on sociodemographic and clinical
parameters was collected during interviews with
the patients. The patients were asked about their
age, age at menopause, marital status, education,
work status, living situation, previous non-vertebral
fractures, vertebral deformities, parental history of
fracture, smoking and drinking alcohol, use of hor-
mone replacement therapy (HRT), use of bisphos-
phonates, calcium and vitamin D supplements. 
Weight and height were measured at the time
of bone densitometry assessments. The body mass
index (BMI) was calculated as body weight/height2
(kg/m2). Body height and weight were measured in
indoor clothes without shoes.
Bone mineral density in the lumbar spine (L1-L4)
and hip total (femoral neck) was measured by dual
energy X-ray absorptiometry (assessed using
a LUNAR DPX device). The women were examined
in a horizontal position for lumbar spine and
femoral neck. The DEXA method involves a very low
radiation dose similar to that of natural background
radiation (~7 μSv/day) [4]. Measurements of bone
mineral content (g) and area (cm2) are provided for
each measurement site. The BMD results are
expressed as areal density in g/cm2. The coefficient
of variation (CV) is 0.7% at the lumbar spine and
1.0% at the hip [5]. The BMD was compared with
an appropriate ethnic and gender matched refer-
ence database, and was expressed as a standard
deviation score (SD) from the mean of either young
adult (T-score) or age matched (Z-score) reference
groups [5]. The WHO has defined osteopenia as 
a T-score < –1.0 but > –2.5, whilst osteoporosis is
defined as a T score of –2.5 or lower [3].
Vertebral morphometry
Vertebral fractures in the L1-L4 section were eval-
uated using the DXA method of vertebral fracture
assessment (VFA) according to Genant criteria. Ver-
tebral deformity was identified when anterior, mid-
dle, or posterior height loss was more than 20%.
Mild fractures were defined as 20-25% height loss.
Moderate and severe wedge, biconcave or com-
pression deformities were defined as more than
25% height loss [6]. Vertebral deformities were
assessed using a Luna Prodigy Advance device.
Information on sociodemographic and clinical
parameters was collected at the same time as BMD
measures.
Biochemistry and markers of bone formation
and resorption
Venous blood samples were collected from post-
menopausal women between 8 a.m. and 10 a.m. on
a day convenient for them. The subjects had been
fasting. Serum specimens were stored at –20°C
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before being analysed. Serum levels of calcium,
phosphate and alkaline phosphatase were meas-
ured by standard methods. At the same time, blood
was collected to determine concentrations of folli-
cle-stimulating hormone (FSH), oestradiol and bone
turnover markers. 
The concentration of FSH was determined using
the Elecsys FSH, while the level of oestradiol was
measured employing the Elecsys Kit.
Bone formation was assessed by measurement
of the serum level osteocalcin (OC) (BGP – Bone Gla
Protein) in the Elecsys N-MID Osteocalcin® CalSet.
Bone resorption was determined by measure-
ment of the serum level of C-terminal type I α-col-
lagen chain telopeptide (CTx) using the B-Cross
Laps® RP Elecsys Kit.
Biochemistry and markers of bone formation and
resorption were examined in the Laboratory of the
Obstetric and Gynaecological Hospital in Poznan. 
Statistical analysis 
Descriptive statistics of all variables are pre-
sented as percentage, mean and SD. Comparisons
between the groups were assessed by Student’s 
t-tests for parametric values or Mann-Whitney
U test and χ2 test for non-parametric values. The
t-test was employed for statistical comparison of
mean levels of biochemistry and markers of bone
formation and resorption.
Regression analysis was used to determine fac-
tors predicting BMD for lumbar spine, femoral neck
and hip total among 253 women with reduced
BMD, evaluate their significance and assess the
proportion of variance explained by them. The
regression model analysed the following variables:
age, body mass index (BMI), previous fragility frac-
tures, vertebral deformities, parental history of frac-
ture, HRT, use of bisphosphonates, use of calcium
and vitamin D supplements, sedentary lifestyle, cur-
rent smoking, serum FSH, serum oestradiol, serum
osteocalcin, serum CTx, serum alkaline phos-
phatase, serum calcium and serum phosphate. 
Factors such as age, BMI, serum FSH, serum
oestradiol, serum osteocalcin, serum CTx, serum cal-
cium and serum phosphate were treated as con-
tinuous variables. On the other hand, previous
fragility fractures, vertebral deformities, parental
history of fracture, HRT, use of bisphosphonates,
use of calcium and vitamin D supplements, seden-
tary lifestyle and current smoking were classified
as either present or absent. The BMD values for
femoral neck and hip total of the participants did
not differ significantly. For this reason, the multi-
factorial analysis was performed jointly for BMD
values measured for femoral neck and hip total.
The limit of significance was set at p < 0.05 for
all analyses. All statistical analyses were carried out
using SPSS for Windows Version 14.
Results
Most women from the study groups were mar-
ried, lived with their families and had a secondary
education. A significant difference (p < 0.01) was
found among the two groups for age and work sta-
tus (retired). Women from the study groups did not
differ significantly regarding marital status, educa-
tion, living conditions or paid work (Table I). 
Table II presents BMD values (T-score and g/cm2)
for lumbar spine, femoral neck and hip total. The
BMD was evaluated based on the T-score for L1-L4
and for femoral neck (hip total): mean T-score was
–3.11; –3.1 (–3.0) for osteoporotic women and –1.9;
–1.7 (–1.71) for the osteopenic group respectively.
The BMD (g/cm2) in subjects with osteoporosis was
0.8; 0.59 (0.58), while in osteopenic women it was
0.91; 0.7 (0.71) respectively. The difference was 
statistically significant for both measurements 
(p < 0.001) (Table II). Table III presents the charac-
teristics of risk factors for reduced BMD.
The BMI in osteoporotic women was lower than
in the osteopenic group. The difference was statis-
tically significant (p < 0.001).
Over 21% of osteoporotic and 27% of osteopenic
patients had a history of non-vertebral fractures.
None of the subjects sustained a femoral neck frac-
ture. On the other hand, wrist or forearm fractures
occurred in almost 12% of osteoporotic patients and
17% of osteopenic subjects. Parental history of frac-
ture was reported by 38% of women with osteo-
porosis and 41% of patients with osteopenia. Hip
fracture was recorded in 1 parent of osteoporotic
women; parents of osteopenic patients did not sus-
tain any hip fractures. On the other hand, wrist or
forearm fractures were reported in 28.2% of par-
ents of osteoporotic subjects and 32.1% of parents
of osteopenic women. Mild vertebral deformities
were found in 21.2% of osteoporotic patients and
8.9% of the osteopenic group.  14.1% of patients
with osteoporosis and 12.5% with osteopenia were
current cigarette smokers.
Almost 50% of women in both groups led
a sedentary lifestyle. Table IV shows drug treatment
in the groups. Osteoporotic and osteopenic patients
were taking bone active treatment at the time of
the study (HRT, bisphosphonates or calcium sup-
plementation with vitamin D). The HRT was used
by 40% of osteoporotic patients and 47% of
osteopenic women. 
Bisphosphonates were administered to 70.6%
of osteoporotic women: 60% of this group under-
went only bisphosphonates therapy (47.1% with
alendronate administered weekly and 12.9% with
daily doses of alendronate; the time since the 
first alendronate administration was more than 
3 months), while 10.6% of the women received both
bisphosphonates (alendronate administered week-
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Parameter  Osteoporotic patients Osteopenic patients Value of p
(T-score ≤ –2.5) n = 85 (–2.5 < T-score ≤ –1.0) n = 168
Age, mean (SD) [years] 59.9 (5.2) 57.8 (4.8) < 0.01
Education, n (%) 0.248a
Basic  2 (2.4) 8 (4.8)
Work-related 10 (11.8) 17 (10.1)
Secondary 49 (57.6) 78 (46.4)
University level 24 (28.2) 65 (38.7)
Marital status, n (%)
Married 55 (64.7) 105 (62.5) 0.883b
Widowed 13 (15.3) 22 (13.1) 0.839b
Single 7 (8.2) 15 (8.9) 0.999b
Divorced 10 (11.8) 26 (15.5) 0.541b
Living situation, n (%) 0.614a
With family or with another 64 (75.3) 133 (79.2)
Living alone  21 (24.7) 35 (20.8)
Work status, n (%)
Paid work  16 (18.8) 55 (32.7) 0.095b
Retired 69 (81.2) 113 (67.3) < 0.01b
Student’s t-test, aχ2 test, bMann-Whitney U test
Table I. Sociodemographic characteristics of women in groups
Parameter  Osteoporotic patients Osteopenic patients t (d.f.), 
(T-score ≤ –2.5)  (–2.5 < T-score ≤ –1.0)  value of p
n = 85, Mean (SD) n = 168, Mean (SD)
T-score L1-L4 –3.11 (0.65) –1.9 (0.53) 13.9 (196), < 0.001
Bone mineral density (BMD) L1-L4 [g/cm2]  0.8 (0.08) 0.91 (0.13) 6.6 (196), < 0.001
T-score femoral neck –3.1 (0.44) –1.7 (0.49) 13.9 (196), < 0.001
BMD femoral neck [g/cm2]  0.59 (0.06) 0.7 (0.11) 6.6 (196), < 0.001
T-score hip total –3.0 (0.42) –1.71 (0.47) 13.9 (196), < 0.001
BMD hip total [g/cm2]  0.58 (0.05) 0.71 (0.12) 6.6 (196), < 0.001
Significance by t-test for independent samples
Table II. Bone mineral density measurements
ly) and HRT. Moreover, 29.4% of osteoporotic sub-
jects underwent only HRT. 22.6% of osteopenic
women were treated with bisphosphonates: 3.6%
of this group underwent only bisphosphonates ther-
apy, while 19% of the women received bisphos-
phonates and HRT at the same time. Fourty-seven
percent of osteopenic patients underwent HRT: 28%
of this group received only HRT, while 19% of the
subjects received both bisphosphonates and HRT. 
Over 75% of women with osteoporosis and
almost 50% of women with osteopenia had been
receiving daily doses of 500 mg calcium and 400 IU
vitamin D longer than 3 months (Table III).
Table IV shows the mean levels of hormones,
bone markers and serum calcium, phosphate and
alkaline phosphatase. All the subjects had FSH con-
centration, oestradiol level, serum calcium, phos-
phate and alkaline phosphatase within the normal
range. Women with osteoporosis and osteopenia
who did not take bisphosphonates had poorer
serum markers of bone formation and resorption.
The t-test revealed that OC and CTx levels signifi-
cantly differed between the osteoporosis women
and the osteopenic group. Serum OC for osteo-
porotic women with bisphosphonates therapy was
12.96 ng/ml, for patients without bisphosphonates336 Arch Med Sci 2, April / 2012
therapy it was 16.73; the difference was statistically
significant (p < 0.025). Serum OC for women with
osteopenia with bisphosphonates therapy was
16.41 ng/ml, for women without bisphosphonates
therapy it was 19.86 ng/ml; the difference was sta-
tistically significant (p < 0.003). Serum CTx for
osteoporotic women with bisphosphonates thera-
py was 0.193 ng/ml, for patients without bisphos-
phonates therapy it was 0.301 ng/ml; the difference
was statistically significant (p < 0.003). Serum CTx
Parameter  Osteoporotic patients Osteopenic patients Value of p
(T-score ≤ –2.5)  (–2.5 < T-score ≤ –1.0) 
n = 85 n = 168
Body mass index (BMI), mean (SD) [kg/m2]  22.3 (3.1) 24.7 (4.1) < 0.001
Age at menopause, mean (SD) [years] 49.7 (4.5) 48.5 (5.2) 0.134 
Previous non-vertebral 
Fractures, n (%) 18 (21.2) 46 (27.4) 0.236a
Hip fracture, n (%) 0 0
Wrist or forearm, n (%) 10 (11.8) 29 (17.3)
Other, n (%) 8 (9.4) 17 (10.1)
Mild vertebral deformities, n (%) 18 (21.2) 15 (8.9) 0.041b
Parental history of fracture, n (%) 32 (38) 69 (41) 0.163a
Hip fracture, n (%) 1 (1.2) 0
Wrist or forearm, n (%) 24 (28.2) 54 (32.1)
Other, n (%) 7 (8.2) 15 (8.9)
Drinking alcohol, n (%) 0 0
Current smoking, n (%) 12 (14.1) 22 (13.0) 0.944b
Past smoking, n (%) 18 (21.2) 75 (44.6) 0.048b
Never smoking, n (%) 55 (64.7) 71 (42.4) 0.042b
Current sedentary, n (%) 36 (42.3) 91 (54.2) 0.142a
Current physical activity 1-2 times per week, n (%) 47 (55.3) 67 (39.9)
Physical activity in the past, n (%) 2 (2.4) 10 (5.9)
Student’s t-test, aχ2 test, bMann-Whitney U test
Table III. Comparison of risk factors across the groups
Parameter  Osteoporotic patients Osteopenic patients Value of p
(T-score ≤ –2.5)  (–2.5 < T-score ≤ –1.0) 
n = 85 n = 168
Hormone replacement therapy, n (%) 34 (40.0) 79 (47.0)  0.350
Hormone replacement therapy only, n (%) 25 (29.4) 47 (28.0)
Hormone replacement therapy  9 (10.6) 32 (19.0)
and bisphosphonates therapy, n (%)
Bisphosphonates therapy, n (%) 60 (70.6) 38 (22.6) 0.024
Bisphosphonates therapy only, n (%) 51 (60.0)
Weekly alendronate 40 (47.1) 6 (3.6)
Daily alendronate 11 (12.9) 0 0.35
Bisphosphonates (weekly alendronate)  9 (10.6) 32 (19.0)
and hormone replacement therapy, n (%)
Calcium and vitamin D supplements, n (%) 64 (75.3) 83 (49.4) 0.018
χ2 test
Table IV. Drug treatment in the groups
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for osteopenic women with bisphosphonates ther-
apy was 0.274 ng/ml, for women without bisphos-
phonates therapy it was 0.373 ng/ml; the difference
was statistically significant (p < 0.003). The con-
centrations of the markers of bone formation (OC)
and resorption (CTx) in osteoporotic and osteopenic
women significantly depended on their use of bis-
phosphonates. Since the processes of bone for-
mation and resorption are interrelated, the use of
antiresorptive medications reduces both bone
resorption and formation.
Multiple regression analysis for lumbar spine
showed associations with (1) age (reduced BMD
with increasing age), (2) parental history of fracture
(reduced BMD with parental history of fracture), 
(3) use of HRT (reduced BMD in women not using
hormone replacement therapy), (4) use of bispho-
sphonates (reduced BMD in women not using bis-
phosphonates), (5) use of calcium and vitamin D
supplements (reduced BMD in women not using
calcium and vitamin D supplements), (6) serum
oestradiol level and BMI (better BMD with higher
serum oestradiol and BMI). All the variables togeth-
er explain 40.4% of variance in BMD. The greatest
impact on BMD was observed for bisphosphonates
therapy. The second variable in terms of the size of
impact was BMI. Variables with the least influence
were the use of HRT and parental history of fracture
(Table VI). Multiple regression analysis for femoral
neck and hip total showed associations with (1) age,
(2) parental history of fracture, (3) use of bisphos-
phonates, (4) use of calcium and vita  min D supple-
ments, (5) serum oestradiol level. All the variables
together explain 25.6% of variance in BMD. Variables
related to BMD for both lumbar spine and femoral
neck (hip total) included age, parental history of 
fracture, bisphosphonates therapy, calcium and vita-
min D supplements, and serum oestradiol level.
Neither analysis found a correlation between
reduced BMD and vertebral deformities, sedentary
lifestyle, current smoking, serum osteocalcin, CTx
or any of the other biochemical measures. 
Discussion
Our investigation showed that older age,
parental history of fracture, low BMI, not using bis-
Biochemistry and markers Osteoporotic patients  Osteopenic patients t (d.f.), value of p
(normal range)( T - score ≤ –2.5) (–2.5 < T-score ≤ –1.0)
n = 85, Mean (SD) n = 168, Mean (SD)
Serum FSH [mIU/ml] (25.8-134.8) 71.71 (17.87) 75.38 (28.35) 1.25 (239), 0.211 
Serum oestradiol [pg/ml] (< 5.0-54.7) 19.41 (30.44) 18.01 (18.2) 0.46 (251), 0.647
Serum alkaline phosphatase [U/l] (35-104) 68.77 (33.13) 70.18 (24.31) 0.38 (251), 0.703
Serum calcium [mmol/l] (2.15-2.55) 2.4 (0.17) 2.57 (1.99) 0.76 (251), 0.446
Serum phosphate [mg/dl] (2.7-4.5) 3.68 (0.49) 3.52 (0.55) 2.27 (251), 0.024
Serum osteocalcin [ng/ml] 14.24 (7.4) 18.47 (7.38) 4.29 (251), < 0.001
Serum CTx [ng/ml] 0.23 (0.16) 0.33 (0.18) 4.78 (251), < 0.001
Significance by t-test for independent samples 
Table V. Biochemistry and markers of bone formation and resorption in patients with osteoporosis and osteopenia
Predictors of BMDU nstandardized coeficient Standardized coeficient Value of t Value of p
BS E β
Constant –0.570 1.001 – –0.570 0.569
Age –0.040 0.011 –0.166 –3.485 0.001
Parental history of fracture –0.224 0.114 –0.083 –1.962 0.050
Hormone replacement therapy  –0.294 0.138 –0.093 –2.129 0.034
Bisphosphonates therapy –0.765 0.138 –0.285 –5.545 < 0.001
Calcium and vitamin D supplements –0.437 0.132 –0.171 –3.308 0.001
Serum  oestradiol 0.005 0.002 0.136 2.737 0.007
BMI 0.069 0.014 0.222 5.055 < 0.001
F(21. 362) = 14.35, p < 0.001, adjusted R2 = 40.4%
Table VI. Variables associated with BMD in postmenopausal women with reduced bone mineral density evaluated
by multiple regression analysis for the lumbar spine
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phosphonates, not using HRT, not using calcium
and vitamin D supplements, and serum oestradiol
were risk factors in predicting those with reduced
BMD for lumbar spine among postmenopausal
women. These factors combined accounted for
40.4% of the variability in BMD. At the same time,
age, parental history of fracture, bisphosphonates
therapy, calcium and vitamin D supplements and
serum oestradiol were risk factors in predicting
those with reduced BMD for femoral neck and hip
total. These factors combined accounted for 25.6%
of the variability in BMD. The greatest impact on
BMD for lumbar spine was observed for bisphos-
phonates therapy. Numerous clinical trials have con-
firmed the beneficial effect of bisphosphonates on
BMD [7]. An example may be a study of 8710
patients, which showed that ibandronate treatment
enhanced BMD and reduced the incidence of osteo-
porotic fractures [8]. A different study assessed the
effect of teriparatide use in postmenopausal osteo-
porotic women. The participants were divided into
two groups. Group I received 20 mg teriparatide dai-
ly for 18 months. The other group was treated with
weekly doses of 70 mg alendronate. Moreover, each
patient received 1 g Ca and 800 IU vitamin D daily.
The authors investigated the effect of the therapy
on the concentration of bone turnover markers. The
conclusion was that teriparatide treatment of osteo-
porosis is superior to the use of bisphosphonates
in protecting bones from fractures and improving
the quality of life with regard to the performance
of daily work [9]. According to our findings, the sec-
ond variable in terms of the size of impact on
reduced BMD for lumbar spine was BMI. The BMD
improves with increasing BMI. The role of low
weight and low BMI as risk factors for future occur-
rence of fractures has been well documented [10].
Population studies showed that low BMI consider-
ably increased the age-specific risk of all fracture
types [11]. The fracture risk for the proximal femur
was almost twofold higher in subjects with BMI of
20 kg/m2 than in those with BMI of 25 kg/m2. 
Variables with the least influence were the use
of HRT and parental history of fracture. Reduced
BMD is related to age and menopause and associ-
ated with oestrogen deficiency. The imbalance
between bone resorption by osteoclasts and bone
formation by osteoblasts leads to osteopenia and,
subsequently, osteoporosis. The present study
revealed that women not using HRT had lower
BMD. We also found a protective effect of serum
oestrogen on BMD of our women. A longitudinal
study conducted by Hannan et al. showed that
women who used HRT at the time of the study
tended to have less bone loss. The protective effect
of HRT on bone loss was not observed for all BMD
sites in the 32 oestrogen users [12]. A protective
effect of oestrogen and serum oestrogen levels on
BMD has been reported in cross-sectional and lon-
gitudinal studies [13]. Studies of the Framingham
cohort showed that women not using HRT had low-
er BMD than users [14]. The study of Osteoporosis
Fractures reported that current users of HRT had
33% lower rates of bone loss than non-users [15],
similarly to the effects in the Hannan et al. study,
although a statistically significant difference was
noted only for the trochanter [12]. The mechanism
of oestrogen effect on bone metabolism is complex
and it has not been fully elucidated so far. Research
suggests that it may reduce formation and stimu-
late apoptosis of osteoclasts and exert an additional
effect on homeostasis of calcium compounds. Estro-
gens bind and activate two different oestrogen
receptors, ERα and ERβ, which have been found in
osteoblasts, osteoclasts and stromal cells of the
bone marrow. Numerous reports indicate that estro-
gens may directly regulate osteoclasts [16]. Study
findings also show that these hormones exert an
indirect effect on osteoclasts by inhibiting the for-
mation of cytokines, i.e. activators of bone resorp-
tion, in osteoblasts and stromal cells of the bone
marrow [17]. Parental history of fracture predicts
reduced BMD, which may suggest that genetic pre-
disposition influences the rate and degree of BMD
loss. Our investigation showed a very weak corre-
Predictors of BMDU nstandardized coeficient Standardized coeficient Value of t Value of p
BS E β
Constant –0.580 1.211 –0.471 0.549
Age –0.040 0.011 –0.166 –3.485 0.001
Parental history of fracture 0.348 0.207 0.224 1.685 0.049
Bisphosphonates therapy –0.665 0.238 –0.245 –4.345 < 0.03
Calcium and vitamin D supplements –0.514 0.244 –0.338 –2.106 0.039
Serum oestradiol 0.007 0.004 0.244 1.739 0.047
F(22. 68) = 1.76, p = 0.03, adjusted R2 = 25.6%
Table VII. Variables associated with BMD in postmenopausal women with reduced bone mineral density evaluated
by multiple regression analysis for femoral neck and hip total
Grażyna Bączyk, Tomasz Opala, Paweł Kleka, Marek ChuchrackiArch Med Sci 2, April / 2012 339
lation between parental history of fracture and
reduced BMD. The latest papers describe a statis-
tically significant importance of parental history of
hip fracture for the assessment of ten-year proba-
bility of fractures [18, 19]. In our study, parental his-
tory of hip fracture was reported for only 1 person
and the analysis took into account all non-vertebral
parental fractures. The above might be an expla-
nation of the very weak correlation (at the level of
p = 0.05) between parental history of fracture and
reduced BMD. Studies conducted to date have
found that postmenopausal women whose moth-
ers suffered from osteoporosis had lower BMD and
were more susceptible to fractures than women in
the control group whose mothers were not osteo-
porotic. Numerous epidemiological studies confirm
the importance of a positive family history of moth-
er’s osteoporosis as a factor increasing the risk of
fractures [20]. The present study did not find a cor-
relation between BMD and vertebral deformity 
(p = 0.123). Only mild vertebral deformities were
reported in 21.2% of osteoporotic subjects and 8.9%
of osteopenic women, and the multifactorial analy-
sis did not reveal a relationship between this vari-
able and BMD of the patients.
Calcium is an important nutritional factor for
bone health. A review by Heaney of 139 reports
investigating the role of calcium on bone mass con-
cluded that calcium has positive effects on bone
mass throughout life [21]. Diet of postmenopausal
women very frequently contains insufficient
amounts of calcium and vitamin D. Inadequate sup-
ply of vitamin D reduces absorption of calcium from
the digestive system, at the same time increasing
bone turnover and susceptibility to osteoporotic
fractures. Supplementation of vitamin D has been
demonstrated to decrease the bone loss in the
femoral neck of postmenopausal women but its
effectiveness in reducing the risk of fractures seems
ambiguous. According to Lips et al. [22], vitamin D
(400 IU a day) administered without calcium did
not reduce the risk of fractures in male and female
subjects, while Trivedi et al. [23] found that intake
of 100,000 IU vitamin D every four months
decreased the incidence of fractures. Similarly, large
doses of vitamin D administered as intramuscular
injections once a year reduced the number of
humeral fractures among Finnish women. Numer-
ous studies indicate that treatment combining cal-
cium and vitamin D has a beneficial effect on BMD
of the spine, femoral neck and whole skeletal sys-
tem in postmenopausal women. Moreover, a ther-
apy combining calcium and vitamin D reduces the
incidence of fractures. In the study of Chapuy et al.,
the proportion of femoral neck fractures and non-
vertebral fractures fell from 43% to 32% after 18
months of calcium and vitamin D supplementation
[24]. However, the Research Council of the United
Kingdom published different findings of a random-
ized trial using a factor analysis that aimed to
assess the effectiveness of therapy consisting in
oral administration of vitamin D and calcium every
day for secondary prevention of low-trauma frac-
tures in women. The study did not show a signifi-
cant reduction in incidence of fractures as a result
of calcium and vitamin D supplementation [25].
Nevertheless, the majority of trials confirm the ther-
apeutic effect of calcium and vitamin D consisting
in prevention of fractures in persons with calcium
and vitamin D deficiency [26]. According to the find-
ings of Rabenda et al., the bone quality may be
increased during treatment by changing the
microstructure of bone in the absence of a change
in BMD. Calcium and/or vitamin D may exert an
anti-fracture effect through a mechanism inde-
pendent of bone density [27]. 
The present study did not consider the time of
breast-feeding and the effect of this variable on
BMD of post-menopausal women, but it would be
worthwhile to quote the findings of research eval-
uating the effect of breast-feeding duration on BMD
of Turkish postmenopausal women. The retrospec-
tive study enrolled 587 postmenopausal women,
who were divided into 4 groups depending on the
time of breast-feeding and into 3 groups based on
their DEXA results. The authors found a correlation
between the time of breast-feeding and the BMD
score for femur and spine. However, the findings do
not reveal a relationship between duration of
breast-feeding and BMD of patients [28].
Markers of bone turnover represent a more spe-
cific and sensitive measure of the process than con-
ventional tools used to date. They assess the 
current bone turnover, just as BMD provides 
information on the status of the skeletal system.
The markers reflect early changes in the bone
metabolism, which help clinicians not only diag-
nose osteoporosis but also monitor antiresorptive
therapy. The multifactorial regression analysis in our
study did not indicate the level of the bone turnover
markers as a predictor of BMD. Most studies have
demonstrated that biochemical markers of bone
formation and resorption have been used to pre-
dict bone loss and response to treatment of osteo-
porosis with bisphosphonates and HRT in post-
menopausal women [29]. The results of the study
by Sypniewska et al. demonstrate a relative imbal-
ance between bone formation and resorption asso-
ciated with fragility fracture in elderly women with
low vitamin D status. Additionally, the authors sug-
gest that compensatory elevation of serum osteo-
protegerin, particularly with reduced bone forma-
tion, is insufficient to limit bone loss leading to
fracture [30].
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The major limitations of our study are as follows.
First, a follow-up study has not been conducted e.g.
after a year. Second, the assessment included a lim-
ited number of biochemical parameters and bone
turnover markers. Third, the effect of double-action
medications was not evaluated. The last limitation
was due to the fact that at the time of the study
only antiresorptives were used in the patients and
not double-action agents.
In conclusion, the present study demonstrated
correlations between the variables and BMD, which
are known and widely described in the literature.
Older age, parental history of fracture, low BMI, not
using bisphosphonates, not using HRT, not using
calcium and vitamin D supplements and serum
oestradiol appear to be the main predictors of
reduced BMD among postmenopausal women in
our investigation. 
Osteoporosis and osteopenia in Polish subjects
appear to be associated with several known risk
factors that are well described in the literature. 
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